258870-50-7

Basic information

• Product Name: (2S,3R)-3-{(S)-1-[5-(3-Chloro-4-fluoro-phenyl)-pyridin-3-ylmethyl]-2-oxo-azepan-3-ylcarbamoyl}-5-methyl-2-propyl-hexanoic acid tert-butyl ester
• CAS NO: 258870-50-7
• Molecular Weight: 602.189
• Mol File: 258870-50-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,3R)-3-{(S)-1-[5-(3-Chloro-4-fluoro-phenyl)-pyridin-3-ylmethyl]-2-oxo-azepan-3-ylcarbamoyl}-5-methyl-2-propyl-hexanoic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R)-3-{(S)-1-[5-(3-Chloro-4-fluoro-phenyl)-pyridin-3-ylmethyl]-2-oxo-azepan-3-ylcarbamoyl}-5-methyl-2-propyl-hexanoic acid tert-butyl ester(258870-50-7)
• EPA Substance Registry System: (2S,3R)-3-{(S)-1-[5-(3-Chloro-4-fluoro-phenyl)-pyridin-3-ylmethyl]-2-oxo-azepan-3-ylcarbamoyl}-5-methyl-2-propyl-hexanoic acid tert-butyl ester(258870-50-7)

Safety Data

• Hazardous Substances Data: 258870-50-7(Hazardous Substances Data)

Upstream product

• 148415-75-2 (2R,3S)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid 
• 76944-95-1 tert-butyl N-[(3S)-2-oxoazepan-3-yl]carbamate 
• 120277-69-2 5-bromo-pyridin-3-ylmethyl chloride 
• 258870-72-3 [1-(5-bromo-pyridin-3-ylmethyl)-2-oxo-azepan-3-yl]-carbamic acid tert-butyl ester 
• 219615-42-6 2(R)-[1(S)-(tertbutoxycarbonyl)-butyl]-4-methyl-valeric acid 
• 258870-64-3 (2S,3R)-3-[(S)-1-(5-Bromo-pyridin-3-ylmethyl)-2-oxo-azepan-3-ylcarbamoyl]-5-methyl-2-propyl-hexanoic acid tert-butyl ester 
• 144432-85-9 3-chloro-4-fluorophenylboronic acid 

Relevant articles and documents

Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors

The synthesis, evaluation, and structure-activity relationships of a series of succinoyl lactam inhibitors of the Alzheimer's disease γ-secretase are described. Beginning with a screening hit with broad proteinase activity, optimization provided compounds with both high selectivity for inhibition of γ-secretase and high potency in cellular assays of Aβ reduction. The SAR and early in vivo properties of this series of inhibitors will be presented.